This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): RRx001
Description: Limited information is available for RRx-001, but the company has disclosed that it is based on a proprietary dinitroazetidine scaffold that increases reactive oxygen and nitrogen species (RONS) production. This in turn is believed to increase expression of epigenetically-repressed genes that may be involved in multiple tumor pathways including p53.
Additional information available to subscribers only: